Form 4: BMY Director Rice Acquires Deferred Share Units

Bristol-Myers Squibb Director Derica W. Rice acquired 831.486 Deferred Share Units as part of her compensation, increasing her total beneficial ownership to 33,784.279 units.

Summary

• Derica W. Rice, a Director at Bristol-Myers Squibb Co. (BMY), acquired 831.486 Deferred Share Units (DSUs).
• The transaction occurred on September 30, 2025.
• Following this acquisition, Ms. Rice beneficially owns a total of 33,784.279 DSUs.
• Each DSU will be converted into one share of common stock upon settlement.
• Settlement of the DSUs will occur when Ms. Rice ceases to be a director or at a previously specified future date.
• The acquisition includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
• The transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The filing reports a routine, expected insider transaction related to director compensation. It reflects standard corporate governance practices and aligns director interests with shareholders, which is generally positive, but does not indicate any new material financial or operational developments.

Positives

• The acquisition of Deferred Share Units by a director aligns their financial interests with those of shareholders, promoting long-term value creation.
• The transaction is part of a structured compensation plan, indicating stable and transparent corporate governance practices for director remuneration.
• The use of a Rule 10b5-1(c) plan demonstrates a pre-arranged and transparent approach to insider transactions, reducing concerns about opportunistic trading.

Future Outlook

Deferred Share Units will be converted into shares of common stock upon the reporting person ceasing to be a director or at a future date previously specified by the reporting person.

Industry Context

The acquisition of Deferred Share Units (DSUs) as part of non-employee director compensation is a common practice across various industries, including the pharmaceutical sector. This method aligns director interests with long-term shareholder value by deferring equity compensation until a future date, often post-service.

Comparison to Industry Standards

• The use of Deferred Share Units (DSUs) for non-employee director compensation is a standard practice, comparable to compensation structures at peer pharmaceutical companies such as Pfizer (PFE), Merck & Co. (MRK), and Johnson & Johnson (JNJ), which also utilize equity-based awards to align director incentives with shareholder returns.
• The acquisition price of $0 for DSUs is typical for compensation grants, reflecting their nature as a form of deferred equity rather than a direct purchase.

Stakeholder Impact

• Shareholders: Increased alignment of the director's financial interests with long-term shareholder value.

Next Steps

• Settlement of the Deferred Share Units into common stock when the reporting person ceases to be a director or at a future date previously specified.

Key Dates

Recommendation

This Form 4 filing details a routine acquisition of deferred share units by a director as part of their compensation, executed under a Rule 10b5-1 plan. Such transactions are standard practice for non-employee directors and do not typically signal a material change in the company's operational performance, financial outlook, or strategic direction. Therefore, it does not provide a basis for a change in investment recommendation, and a 'hold' stance is appropriate as the filing itself does not present new information warranting a buy or sell decision.

Keywords

Bristol-Myers Squibb, BMY, Form 4, Insider Transaction, Director Compensation, Deferred Share Units, Equity Compensation, Derica W. Rice, Rule 10b5-1